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describes the Dutch charter on a safety management system that sets 
out to perform a regular risk inventory, create a system for blame-
free reporting, develop a system for data analysis and to put a system 
in place for implementation of improvements. 
However incident reporting is only one element of risk management 
and should be seen as a tool to facilitate analysis and identify where 
change will be most effective.   A range of methodologies can be used 
to assess and manage risk including Failure Mode and Effects Analysis 
(FMEA), Root Cause Analysis (RCA) Events and Causa lFactors Analysis 
(ECFA) and incident reporting, investigation and analysis.    
Methodologies can be simple or very complex and are applicable in 
different settings but basically involve identifying factors that have 
led or could lead to incidents occurring and considering strategies to 
manage these factors.      
It is also necessary to consider the organization and the environment 
in which radiotherapy is prepared and delivered and the personnel 
involved as these can also contribute to risk. As systems become more 
complex they become less transparent with greater opportunity for 
incidents to occur. Analysis of the functioning of the organization and 
its personnel can be facilitated by regular audit identifying risk areas.  
Risk management should be seen as a proactive process designed to 
improve quality by reducing risk and the number of incidents that 
occur in our departments.    Incident reporting and analysis is of no 
benefit without feedback and involving all appropriate staff in 
addressing the findings and implementing change.  It is the 
responsibility of all professionals involved in the process and is most 
effective when a strong safety culture exists that is is actively 
supported with research and education. Finally risk management 
involves informing patients and the public in a timely and open 
manner to avoid speculation and sensationalism and ensure that 
radiotherapy is seen as an area where risk and its management is 
integral to practice. 
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Purpose/Objective(s): The current era of evidence-based medicine 
demands rigorous analysis and modeling of treatment outcomes data 
to understand treatment efficacy, patient response, and design 
successful future clinical trials. Statistical methods play a pivotal role 
in evidence-based medicine for developing response models from 
biological and clinical data of individualized prognostic or predictive 
outcomes. In this tutorial, we will provide an overview of various 
statistical methods applied in radiotherapy for fitting of 
response/biological models to dosimetric and clinical data in radiation 
oncology.  
Materials/Methods: Outcomes in radiotherapy are characterized by 
models of tumor control probability (TCP) and the surrounding normal 
tissue complication probability (NTCP). These models could be applied 
to optimize and evaluate the quality of different treatment planning 
modalities and are used in designing new radiotherapy clinical trials 
by estimating the expected therapeutic ratio of new protocols. A 
review of basic analytical and data-driven methods will be provided. 
Different statistical methods in both approaches using case studies 
and examples from our work and others in the literature will be 
presented.    
Results:  A step-by-step approach for the development of response 
TCP/NTCP models will be presented. In case of analytical models, 
parameters and outcomes confidence intervals will be assessed. In 
case of data driven-models, issues related to coding of categorical and 
continuous variables, collinearity, parsimony principle, dimensionality 
reduction, and endpoint type would be discussed. Strategies for 
dealing with missing data,imbalance events, overfitting, and model 
generalizability will be highlighted.   
Conclusions: The main goal of this tutorial is to familiarize the 
radiotherapy practitioner with the different statistical methods for 
building and evaluating radiobiological models of a clinical endpoint. 
Different examples of TCP/NTCP model development and their 
application in clinical decision-making will be presented along with 
discussion of various inter-related issues. 
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Real-life optimisation problems commonly have to cope with 
competing, but equally important objectives and therefore do not 
possess a unique, unambiguous solution. In fact, a given solution 
becomes the “optimum” only by a selection process, which is often 
interactive. This selection needs to resort to the same elements that 
make navigation in a foreign city effective: 1) each location should be 
accessible, 2) directions should be available, 3) a destination should 
be reached directly and precisely.  
Accessibility. The term "Pareto fontier" has become known for the set 
of all competing solutions of a dose planning problem. The 
configuration, and even existence of this Pareto frontier is far from 
trivial in the general setting of dose planning, which is why usually 
only fluence distributions or idealized dose distributions (instead of 
deliverable plans) and physical cost functions (instead of dose-volume 
and some biological cost functions) are considered. Under these 
conditions, each point of the Pareto front can be reached by an 
unconstrained dose optimisation with a specific priority weight for 
each cost function. A more direct alternative is to turn all but one 
cost function into constraints and employ constrained optimisation, 
which also remains viable in the more general setting.  
Orientation. A very thorough way of getting oriented is to explore 
every possible direction and see where it leads. In dose optimisation, 
each exploration requires a full dose optimisation and is hence time 
consuming. To work around this, navigation tools have been devised 
that rely on a set of pre-computed dose plans, and much effort has 
been devoted to reducing the number of these computations. An 
alternative within the framework of constrained optimisation is 
sensitivity analysis, which predicts the change in one cost function if 
another one is altered (i.e. the slope of the tangent to the Pareto 
frontier). This does not require pre-computation, but is restricted to 
small changes and hence relies on a good start location. 
Arrival. No amount of information can avoid that the route to the 
final choice is a repeated cycle of getting directions and taking a step, 
especially when the number of competing objectives is large. Later 
steps could partially invalidate previous ones. Therefore, it becomes 
essential to treat already established cost function values as 
constraints. Besides for navigation “on foot”, constrained optimisation 
is also the key to various methods of automated route finding (i.e. 
proper simultaneous optimisation of multiple criteria) like 
lexicographic ordering or constraint prioritization. These methods 
capture the trade-off rules the expert would usually employ, and 
apply these rules in an attempt to perform at least the most obvious 
selection steps unsupervised. 
Although multi-criteria algorithms are built on mathematically 
rigorous formalisms, the concepts derive their value from their 
interactive usability and the users´ preference, and are therefore 
ultimately subjective.  
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Over the last few years, positron emission tomography (PET) has 
proved to convey useful information for treatment planning in 
radiotherapy. Within this framework, the most straightforward way to 
exploit this information is to use PET images to delineate a target 
volume. An abundant literature deals with this problem and many 
automatic or semi-automatic methods have been proposed, ranging 
from uptake thresholds to very complex segmentation algorithms. Yet, 
to date, the problem remains unsolved and few (or no) methods seem 
to succeed in combining accuracy (low bias) and precision (low 
variance across a broad range of observers, tracers, tumor sites, 
target size/shape, and camera models). 
Several impediments cause this slow progress. The first and primary 
one includes all intrinsic, physical limitations of PET cameras. Images 
are blurred (positron annihilations are difficult to locate in wide 
gantries and in attenuating material) and noisy (annihilation counts 
are low). Noise is generally attenuated by smoothing the images even 
more heavily. By essence, blur complicates the segmentation 
problem, as it increases the uncertainty about the location of the 
target edges. Other, secondary causes have a methodological nature 
and result from the first one. Most segmentation methods stem from 
simple or very heuristic models that approximate roughly or even 
ignore the aforementioned effects, leading to inaccurate results. On 
the other hand, more complex methods are hindered by an over-
fitting effect: they perform well on data they have been calibrated or 
tested with but they generalize poorly to other images, other camera 
models, etc. This leads us to the third impediment, which is the 
difficulty of validating the candidate methods on sufficient and 
appropriate data. In particular, robustness and reproducibility depend 
on the availability of a large number of images, covering most of the 
experimental domain, in terms of tumor sites, target sizes and shapes, 
camera models, etc. Each image should also come with a ground truth 
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or at least a decent surrogate of it. A last methodological aspect of 
the problem concerns quality assessment, which is not uniform across 
studies, ranging from mild volumetric comparisons to stricter overlap 
indices, or even false positive/negative rates. The combination of all 
these methodological issues, with varying severity from publication to 
publication, makes any comparison or general comparison quite 
hazardous. 
With PET being now quite widely used in radiotherapy, these 
methodological issues cannot be longer overlooked and some groups 
are starting to tackle them. A first effort in this direction has been 
the work conducted together by the ESTRO and EANM, leading to joint 
sessions in their respective congresses and the publication of a special 
issue of Radiotherapy and Oncology. More recently, the AAPM has set 
up task group 211, which aims at gathering data from various sources, 
at clarifying quality assessment, at surveying the literature, and 
categorizing existing methods. Ultimately, this would allow a 
benchmarking tool to be built and made publicly available. This tool 
could also constitute a basis for training users and researchers in the 
domain, with hopefully the development of improved segmentation 
methods at the end of the road. Eventually, from the viewpoint of 
hardware and software, one can expect vendors to address directly 
the problem of segmentation, if not by the integration of 
segmentation tools, then at least by providing dedicated 
reconstruction algorithms and protocols. Any gain in spatial resolution 
or artifact reduction would indeed ease the difficulty of target 
delineation. 
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When young scientists begin their career, they will usually be given a 
project from their supervisor.Initially, they will probably know little 
about the subject or the project but as they begin working and gain 
knowledge, they should start to evaluate it and continue this 
evaluation regularly. This includes the importance of the goals,the 
feasibility of achieving them in the project time, whether the 
approach is optimum one and whether the relevant equipment and 
facilities are available.This is helped by having a good infrastructure 
such that each young scientist has a supervisory committee which 
should meet regularly (e.g. once a year) to evaluate progress of the 
scientist and the project. Specific and general problems can then be 
addressed and the project modified if necessary. If there is not 
already such an infrastructure in place, the scientist should been 
encouraged to press for one to be set up. 
It is also important, especially at the beginning of a scientific career, 
to meet with your direct supervisor frequently, e.g. once per week, to 
discuss you results, approaches to problems,plans, and to maintain 
focus. It is easy to get sidetracked into investigating interesting 
aspects but which are not directly relevant to the primary goals of the 
project. Keeping focus on the main goal will help shorten the time to 
publishing your first paper (an important milestone), getting your PhD, 
and hone your ability to continually to assess what is most important 
to you and your current project. 
Projects can be fundamental or translational, and both are valuable. 
The choice will depend on the interest and motivation of the scientist, 
e.g. does the scientist have a medical background or interest,is the 
primary purpose to improve cancer treatment, or is it to understand 
the response of cells or tissues to various stimuli including the 
different forms of treatment used for cancer (drugs, radiation, 
immunotherapy, anti-vascular approaches, etc)? If you don’t like 
working with animals, for example, make sure your project doesn’t 
demand their use. If you don’t want to study at the hard-core 
molecular biological level, for example, stick to the cultured cell, 
tissue or animal levels.  
Your time will be spent in, firstly, carrying out experiments to 
generate data, and secondly, in the continuous effort to increase your 
knowledge. Although focusing on your goals when planning 
experiments is highly recommended, it is equally important to read 
not just in your subject but around it, increasing your knowledge of 
general cancer biology, molecular biology, and cancer treatments. It 
is recommended to read not just abstracts, not just reviews, but also 
read the directly relevant papers in all their detail. This should also 
develop your critical faculties (is it new? are the data good? do you 
believe their conclusions? if not why not? have they used the best 
approaches? have they used the most optimum methods? etc). It can 
be also very helpful to discuss interesting papers with your 
colleagues,e.g in a literature club format. With regard to your general 
education, it is important and highly recommended to go to scientific 
seminars even if they are not on your specialist subject. Talks from 
some world experts are also available on the web (e.g. from the 
annual AACR meeting) which are often clear,stimulating and of high 
quality, and of course available to everyone wherever you work. 
Further advice is not to work in isolation. However good you are, you 
are likely to benefit from talking and/or working with others. At the 
very least, talk science to your colleagues regularly. Discussions with 
colleagues and attending regular scientific seminars are relatively 
easy in large academic institutes. If this doesn’t apply to you, it is 
recommended to set up collaborations with other groups working on 
similar subjects in other institutes. You are likely to benefit from their 
experience and vice versa, to progress more rapidly in your research, 
and be more competitive.  
Lastly, in terms of your career, you should assess your own 
performance and desires, particularly after three or four years in 
research. Are you naturally curious? Are you good at it? Are you 
enjoying it? Do new findings excite you? Do you come up with ideas (in 
addition to those of your supervisor’s)? Would you make a good group 
leader (supervising a lab with younger scientists, technicians, etc 
under you)? If yes, go for it! If not, it is advised to consider the many 
other possible non-research careers that would take advantage of your 
expertise, including in scientific publishing, various roles in 
pharmaceutical companies, etc. If you are unsure about your ability to 
lead others, to get experience you could try and persuade your 
supervisor to employ a younger student to work for you (e.g. for a 
number of months), or have a technician assigned to you. This can 
provide valuable experience whether or not you remain in a pure 
research position. 
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Intraoperative radiotherapy (IORT) and other recent developments in 
radiotherapy such as stereotactic radiosurgery (SRS), high-dose rate 
(HDR) brachytherapy boost, and stereotactic body radiotherapy (SBRT) 
apply a single or very few, very large fractions of radiation. This 
represents a major departure from conventional, fractionated 
radiotherapy and may produce different biological effects than 
predicted from multiple fractions of 1.8-2 Gy per day. Conventional 
radiotherapy is based on the relative sparing of late reacting normal 
tissue relative to the tumour achieved by giving the total dose in 
multiple fractions.However, irradiation with as few as 1-3 fractions 
has been surprisingly effective with acceptable normal-tissue reaction 
in various clinical settings. In this lecture, a review of various clinical 
and biological factors that may influence the therapeutic efficacy of 
single-dose irradiation will be given. Usually the target for single-dose 
IORT will be residual tumour foci in the tumour bed after excision of 
the tumour. The limited number of tumour cells will affect the dose 
response relative to solid tumours and the volume effect will help 
spare the normal tissue if the volume receiving a high dose is kept 
small. A frequent question is whether the linear-quadratic (L-Q) 
model is valid for comparing is offective doses of single-dose and 
conventionally fractionated radiotherapy. Although it can be argued 
that the L-Q model may not be theoretically exact for comparing the 
biological effect of single-dose with fractionated irradiation, clinical 
values of the essential parameter alpha/beta have wide confidence 
intervals which preclude inferences about the validity of the model. 
Nevertheless, the L-Q model remains useful as a first approximation. 
50 kV X-rays used in some applications of IORT have an increased RBE 
which must be taken into account when comparing effects with MV X-
rays. We have modelled the RBE by the L-Q formalism including 
effects of dose per fraction and dose rate for protracted irradiation 
and validated this by experimental measurements of RBE for cell 
inactivation after irradiation in a tumour-bed phantom. Various 
aspects of the cellular response to large doses of radiation may 
influence cell survival with threshold values most likely in the range 8-
15 Gy. Thus experimental evidence will be presented supporting the 
idea that the repair system responds differently to high single doses 
and that a cohort effect may add to the efficacy. The influence of the 
stroma and the micromilieu will be reviewed and the evidence for a 
role of immunological effects will be discussed.  
